Stay updated with breaking news from Market Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
29.02.2024 - MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) - Knight Therapeutics Inc., (TSX: GUD) ('Knight'), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi (tafasitamab) by its Brazilian affiliate, United Medical ... Seite 1
TORONTO, Nov. 29, 2023 /CNW/ - Vertex Pharmaceuticals Incorporated today announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® for the treatment of...
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz
(2023-10-16 | TSX:GUD) Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and lab quality – – Sets...